source
- Analysts focus on RevMed pancreatic cancer launch and Merck data push ahead of Q3 earningsJohnson & Johnson is set to open the third quarter earnings reporting period, with analysts keen to hear about any business development news and launch execution updates. RevMed’s upcoming launch…
- Paragon spinout Velaris Therapeutics goes public via reverse merger with Alaunos, raising $350 millionParagon Labs, a biotechnology incubator, announced that its latest spinout, Velaris Therapeutics, became a public company through a reverse merger with Alaunos Therapeutics. The transaction places…